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Abstract
Aberrant hyperactivation of the phosphatidylinositol 3-kinase (PI3K) cellsignaling pathway, one of the most prominent cell growth, proliferation and
survival pathways in the human body, has been observed in many forms of
cancer. Upon deregulation, this pathway can facilitate the evasion of programmed
cell death, the stimulation of autonomous growth, and the evasion of regular
growth-inhibitory signals. While it was initially believed that the
dephosphorylation activity of lipid phosphatases served to counteract the pathway
by hydrolyzing phosphatidylinositol(3,4,5)trisphosphate (PtdIns(3,4,5)P3) to
phosphatidylinositol(4,5)bisphosphate (PtdIns(4,5)P2), emerging evidence
suggests that SH2-domain containing inositol 5’ phosphatase 1 and 2 (SHIP1/2)
may in fact facilitate, rather than suppress, oncogenesis in certain contexts. We
hypothesize, therefore, that chemical inhibition of SHIP would decrease
phosphatidylinositol bisphosphate levels, thus reducing downstream activation of
cell survival and proliferation effectors. Previous work in the Kerr lab identified a
SHIP1 selective inhibitor (3AC) that was capable of killing malignant
hematological cells but was ineffective against other, non-hematological
malignancies. Therefore, this study sought to identify further, more effective
inhibitors, particularly those capable of targeting both SHIP1 and SHIP2, as well
as to investigate the overall effect such pan-SHIP inhibition has on blood and
breast cancers. In this study, we identify several lead pan-SHIP inhibitors capable
of preventing the hydrolysis of PtdIns(3,4,5)P3 to PtsIns(3,4)P2. Furthermore, we
demonstrate the ability of these pan-SHIP inhibitors to reduce cell viability and to
effectively kill leukemia, multiple myeloma, and breast cancer cells. In
conclusion, this study suggests that the inhibition of SHIP1 and SHIP2 may hold
great clinical promise as a novel therapeutic approach in the treatment of many
different cancers.
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Introduction

The phosphotidylinositol 3-kinase (PI3K) pathway, a prominent cell
growth and proliferation signal transduction system, is perhaps the most
commonly activated signaling pathway in human cancers (Liu et al., 2009). The
phosphatidylinositol 3-kinase pathway is activated upon the binding of an
epidermal growth factor to a membrane-bound receptor tyrosine kinase. This
binding induces dimerization of the receptor monomers, which are subsequently
autophosphorylated. These phosphorylated monomers serve as binding and
activation sites for PI3-kinases, whose primary biochemical function is to
phosphorylate inositol phospholipids in the plasma membrane. Specifically, these
activated PI3-kinases migrate along the cytosolic side of the cellular membrane
and bind to phosphatidylinositol(4,5)bisphosphate (PtdIns(4,5)P2), adding a
phosphate group to its inositol ring at the 3’ position. This results in the formation
of second messenger, phosphatidylinositol(3,4,5)trisphosphate (PtdIns(3,4,5)P3,
or “PIP3”), which, by acting as a docking site, further activates the
serine/threonine kinase, Akt (also known as protein kinase B, or PKB) (Alberts et
al., 2010).
Activated Akt has many different substrates, and hence, can result in a
multitude of effects. Several of the most notable include inhibition of apoptosis,
evasion of regular growth-inhibitory signals, and the autonomous stimulation of
cellular proliferation. Consistent with these effects, many tumors, including both
hematopoietic and tissue malignancies, present with constitutive activation of the
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PI3K-Akt pathway (Fuhler et al., 2012). Therefore, targeting this signal
transduction system with specific inhibitors may have broad clinical application in
the treatment of multiple cancers (Bunney and Katan, 2010; Harvey and Lonial,
2007).
Common belief maintains that PI3K signaling is naturally counteracted by
the dephosphorylation activity of lipid phosphatases. Phosphatase and tensin
homolog, PTEN, hydrolyzes phosphatidylinositol(3,4,5)trisphosphate to
phosphatidylinositol(4,5)bisphosphate by removing the phosphate group at the 3’
position of the inositol ring (see figure 1). This hydrolysis reduces the activation
of the proto-oncoprotein, Akt, and its downstream effectors promoting cell growth
and survival. As such, PTEN functions as a potent tumor suppressor (Ruela-deSousa et al., 2010). The other class of lipid phosphatase implicated in the PI3K
pathway, SH2-domain containing inositol 5’ phosphatase (SHIP), also hydrolyzes
PIP3 to PIP2, but does so by removing the phosphate group at the 5’ position of
the inositol ring (i.e. taking PtdIns(3,4,5)P3 to PtdIns(3,4)P2; see figure 1) (Kerr,
2011). Based on the well-characterized tumor suppressing action of PTEN, it has
generally been assumed that the intracellular enzymatic activity of SHIP functions
to counteract the PI3K-Akt pathway as well. However, several intriguing
observations and a growing body of literature are beginning to challenge this
view.
While a loss of PTEN has been proven to confer increased susceptibility to
cancer development, a loss of SHIP has not been demonstrated to have the same
effect (Kerr, 2011). Based on recent study, it seems that PtdIns(3,4)P2 actually
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binds the PH domain of Akt more effectively than does PtdIns(3,4,5)P3 (Ma et al.,
2008), hence serving to enhance Akt activation (Sheid et al., 2002), contrary to
PTEN. These findings are further supported by notably increased PtdIns(3,4)P2
levels observed in malignant leukemia cells (Constantini, 2009; Brooks et al.,
2010).
Given that the potent Akt-activating potential of PtdIns(3,4)P2 is directly
facilitated by SHIP, we hypothesize that chemical inhibition of SH2-domain
containing inositol 5’ phosphatase would decrease intracellular PtdIns(3,4)P2
levels, thus reducing the activation of downstream effectors of cell survival and
proliferation. As a result, this study sought to identify compounds capable of
inhibiting both paralogs of SHIP: SHIP1 and SHIP2. Their 38% sequence
homology (Fuhler et al., 2012) suggests that these two copies of the gene evolved
from a common ancestral gene, but now carry out slightly different functions
within the body. SHIP1 expression seems to be restricted to cells from the
hematopoietic lineage and osteolineage (blood and bone marrow-forming cells,
respectively), whereas SHIP2 seems to be ubiquitously expressed in all cells
(Hazen et al., 2009, Rohrschneider et al., 2000). Previous work in the Kerr lab
identified a SHIP1 selective inhibitor, 3 α-aminocholestane (3AC), that
effectively killed multiple myeloma cells in vivo; however, this compound was
relatively insoluble and was largely ineffective against non-hematological
cancers. Via high throughput screening strategies, this study identified several
lead pan-SHIP inhibitors that circumvented the challenges associated with 3AC
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and demonstrated great promise as novel therapeutic agents in the treatment of
breast and hematopoietic cancers.

5
Materials and Methods

Potential Inhibitors
All potential SHIP1/2 inhibitory compounds were synthesized in the organic
chemistry laboratory of Dr. John D. Chisholm at Syracuse University, in
Syracuse, NY. Compounds were derivatives of known SHIP inhibitors belonging
to one of three groups: aminosteroids, tryptamines, or quinolones based on
chemical structure. In total, more than 100 compounds were synthesized and
screened at varying concentrations. Compounds were stored in solid state at
-20°C until ready for use, at which time working stocks of a given concentration
were made according to molecular weight and solubility, as provided by Dr.
Chisholm and lab.

SHIP1
Expression and purification of human recombinant SHIP1 was performed
according to a protocol previously established in the Kerr laboratory. A SHIP1
cDNA expression construct was amplified by PCR from the pMIGR1 (SHIP1)
vector (Tu et al., 2001) and was then inserted into the pET24b bacterial
expression vector at the EcoR1 and Xho1 restriction sites (see figure 2). This
specific insertion created a SHIP1-His tag fusion at the C terminus. The Histagged SHIP1 was then expressed in Escherichia coli Rosetta Gami 2 (DE3) pLys
cells by induction after the addition of 0.5mM IPTG to trigger transcription.
Lastly, SHIP1 was purified using Ni-chelating bead chromatography (Brooks et
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al., 2010). To avoid the effects of repeated freeze/thaw cycles, SHIP1 protein
stock was aliquoted and stored at -20 °C for use within 2 months and at -80 °C for
use up to 6 months. It was found that stocks stored at -80°C maintained
significantly greater enzymatic activity, and therefore, all but stocks currently in
use were stored at -80°C.

SHIP2
While members of the Kerr lab worked to finalize a human SHIP2 protein
purification protocol to be performed in the lab (like that which they have
established for human SHIP1) SHIP2 Lipid Phosphatase, active (E-1000) was
obtained from Echelon Biosciences, Inc. (Salt Lake City, UT). This N-terminal,
His-tagged recombinant human SHIP2 (a truncated form containing SH2 domain
and inositol 5-phosphatase catalytic domain) was also purified from E. coli using
nickel column chromatography. This protein stock had approximately twice the
enzymatic activity of the SHIP1 protein stock purified in-house and therefore, was
used at half the concentration throughout all assays. To avoid the effects of
repeated freeze/thaw cycles, SHIP2 protein stock was aliquoted and stored at
-20°C for use within two months and at -80°C for use up to six months.

PIP3
D-myo-Phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) was obtained
from Echelon Biosciences, Inc. (Salt Lake City, UT), and served as SHIP1/2’s
substrate in all assays. As per manufacturer’s instructions, 1mg PIP3 (P-3908) was
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reconstituted in 1020µl ddH2O. Reconstituted PIP3 was aliquoted and stored at 20°C for up to three months. PIP3 was used at concentration of 1mM in all assays.

Malachite Green Assay to determine SHIP1/2 enzymatic activity
To determine the enzymatic activity of SHIP in vitro, Malachite Green Solution
(K-1501) was obtained from Echelon Biosciences, Inc. and was stored at 4°C,
away from light, for use within six months. Through the course of this project we
found the shelf life of Echelon’s Malachite Green Solution to be shorter than
manufacturer’s suggestion, and used solutions within three to four months.
Malachite Green Phosphatase Detection Assay was conducted as previously
described (Brooks et al., 2010) in accordance with the manufacturer’s protocol. In
this assay, SHIP1/2 was mixed with substrate PtdIns(3,4,5)P3 in the presence of
potential inhibitor in 96-well plates. Inhibitors were dissolved in respective
solvents and tested at final concentrations of 1mM, 500µM, 250µM, and 125µM,
respectively (see figure 3). SHIP1 was prepared using ratio of 15µl SHIP1:285µl
buffer, and SHIP2 was prepared using ratio of 7.5µl SHIP2:292.5µl buffer. Buffer
solution consisted of 50mM HEPES pH 7.4, 100mM NaCl, 1mM MgCl2, and
0.25mM EDTA. 10µl of potential inhibitor was then mixed with 90µl of
SHIP/buffer solution. 3µl PIP3 (1mM) was added to each well, followed by 22µl
of inhibitor/SHIP/Buffer solution. Each reaction was tested in triplicate. The 96well plate was then incubated at 37°C for 20 minutes. After incubation, 100µl of
Malachite Green Solution was introduced to each reaction, which were then
allowed to react in the dark for 20 minutes. Final results were quantified via Gen5
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plate reader at absorbance of 620nm. The darker the color/higher the reading, the
more inorganic phosphate has been liberated (see figure 3), hence indicating a
higher activity of SHIP.

Cell lines studied, obtained from American Type Culture Collection (ATCC)
(Manassas, VA)
K562: 53-year old female, chronic myelogenous leukemia (CML), NB4: 23-year
old female, acute premyelocytic leukemia (APL), HSB2: 11.5-year old white
male, acute lymphoblastic leukemia (ALL), 697: 12-year old male, acute
lymphocytic leukemia (ALL), OPM-2: 56-year old female, myeloma relapse,
MCF-7: 69-year old Caucasian female, breast cancer, MDA MB 231: 51-year old
Caucasian female, breast cancer.
K562, NB4, HSB2, and 697 leukemia cells, as well as OPM-2 multiple
myeloma cells, were routinely maintained in Iscove’s Modified Dulbecco’s
Medium (IMDM) (ATCC) supplemented with 10% fetal bovine serum
(Mediatech, Manassas, VA, USA), whereas MDA-MB-231 and MCF-7 breast
cancer cells were cultured in Eagle’s minimal essential medium (EMEM) with
10% fetal calf serum and L-glutamine.

Dojindo Cell Counting Kit-8 (CCK8)-Cell Viability/Cytotoxicity Assay
Cell viability was determined with Cell Counting Kit-8 from Dojindo as per
manufacturers’ instructions (Dojindo Molecular Technologies, Rockville, MD).
Cells were treated in triplicate for 46 hours at 37°C with increasing concentrations
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of inhibitory compounds or vehicle (5,000 cells/well, 10µl inhibitor/well).
Dojindo CCK-8 solution was added (10µl/well) and cells were allowed to
incubate at 37°C for another 2 hours. During this time, Dojindo’s highly water
soluble tetrazolium salt, WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt] forms a water-soluble
formazan dye upon reduction in the presence of an electron mediator. The
solution changes from colorless to orange upon the production of formazan dye,
and therefore, stronger color corresponds to greater cell viability. This
colorimetric assay is also quantified via the Gen5 plate reader program at an
absorbance of 450nm. The optical density (OD) of compound-treated cells was
divided by the OD of their vehicle control, and the viability was expressed as a
percentage of untreated cells. Results are expressed as mean ± standard error of
the mean (SEM) of three individual experiments (Fuhler et al., 2012).

In vivo toxicity and tumor challenge studies
Prior to challenging mice with malignancies and subsequently treating them with
inhibitors, we first ran toxicity screens of our lead compounds in wildtype
C57Bl/6 mice (The Jackson Laboratory, Bar Harbor, ME). This step is crucial in
determining the ultimate effect of SHIP1/2 inhibition; for example, should we
challenge mice with tumor cells, treat them, and the mice die, how do we know if
it was the cancer that killed them or toxicity of the compound? These initial
toxicity screens provide insight into how well each inhibitor is tolerated by a
living organism. Dosages were dependent upon the particular compound, and
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were administered at several different concentrations per inhibitor. These dosages
ranged from 7.63mg/kg (compound K103) to 28.9mg/kg (compound K102).
Upon completion of toxicity screening, NOD/SCID/γcIL2R (NSG) mice
(The Jackson Laboratory, Bar Harbor, ME) were challenged with 1 × 107 OPM2
cells via intraperitoneal (IP) injection. T cells and B cells of the adaptive immune
system are impaired in these models and therefore, any decrease in tumorigenesis
can de attributed directly to the compounds administered. “Treatment” began 6
hours post IP injection with either compound or vehicle. In our initial study, 3AC
was suspended in a 0.3% Klucel/H2O solution at 11.46 mM and administered via
200µl IP injection. Vehicle-treated mice received 200µL injection of 0.3%
Klucel/H2O solution. The final concentration of 3AC in the treated mice was 60
µM. The mice were then treated with 3AC or vehicle daily for the next 6 days and
then twice per week in the remaining 15 wks of the survival study. Effects were
analyzed via direct observation and measurement, via IVIS imaging (a
visualization method utilizing luciferase bioluminescence), via Hemavet 950S
automated blood cell analyzer, and via flow cytometry (a laser-based, biophysical
technology useful for cell counting, sorting, and biomarker detection). Lead panSHIP inhibitors identified throughout the course of this study are currently being
tested at 5-15mg/kg in 5% DMSO:Saline, 5% DMSO:H2O, or in 100% H2O,
depending upon their solubility.
All in vivo studies were performed with approval from the Committee on
the Humane use of Animals (CHUA) at SUNY Upstate Medical University.
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Results

High-throughput screening identifies novel pan-SHIP inhibitors
To date, the three-dimensional molecular structure of SHIP is not known, and
therefore, designing a particular inhibitor to “fit” and block the SHIP molecule’s
activity is not feasible. Therefore, a high throughput screening method was
adopted such that a multitude of derivatives of known SHIP1/2 inhibitors could
rapidly be analyzed for their ability to prevent the hydrolysis of PtdIns(3,4,5)P3 to
PtdIns(3,4)P2 in vitro. The colorimetric Malachite Green Assay allows for easy
visualization of phosphate release, indicative of phosphatase (in our case, SHIP)
activity. Upon dephosphorylation by SHIP at the 5’ position, a free inorganic
phosphate group is released into the solution, which reacts to form a colored
complex with molybdate/malachite green. This color is then quantified by reading
the absorbance at 620 nm. In other words, the stronger the color, the more potent
the activity of SHIP. In this particular assay, we hoped to see little to no color
change of the Malachite Green Solution. A colorless result (or one with a very
low OD) indicates that SHIP has been inhibited, keeping PIP in the
PtdIns(3,4,5)P3 form, as desired. Throughout the course of this study,
approximately 1/3 of the 100+ compounds screened were determined to inhibit
the dephosphorylation activity of SHIP1 and/or SHIP2 at 1mM. These top “hits”
were then tested against SHIP1 and SHIP2 at lower concentrations, specifically at
500µM, 250µM, and 125µM. After testing each compound at each concentration
in triplicate, in three separate experiments, several compounds emerged as “lead
inhibitors,” capable of blocking the activity of both SHIP1 and SHIP2 better than
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the parent compounds from which all new inhibitors were derived (see figure 4).
The lead pan-SHIP inhibitors that we moved forward with in our study included
four aminosteroids: K118, K141, K142, K179, and one tryptamine: K149, based
on percent inhibition and solubility.

Pan-SHIP inhibition reduces the viability of blood and breast cancer cells exvivo
Upon identifying the most potent pan-SHIP inhibitors in vitro using the
Malachite Green Assay, we then wanted to test the ability of these compounds to
kill live cancer cells of both the hematopoietic and non-hematopoietic domains.
Previous work in the Kerr lab demonstrated the ability of SHIP1-selective
inhibitor 3AC to reduce the viability of malignant hematopoietic cells (OPM2
cells-multiple myeloma) in vitro and in vivo (Brooks et al., 2010). However,
because SHIP1 expression is restricted to the hematopoietic compartment, the
potential clinical applicability of 3AC is likewise restricted, feasible only in the
treatment of blood cancers. By also targeting SHIP2, which is ubiquitously
expressed in cells throughout the body, it was our hope that lead pan-SHIP
inhibitors would demonstrate the ability to target and kill a broader range of
malignancies.
As shown in figure 5, the parent pan-SHIP inhibitors from which our new
compounds have been derived (3AC, 1PIE, 2PIQ, 6PTQ) demonstrate notable
killing potential against OPM2 multiple myeloma cells, as well as against MDAMB-231 and MCF-7 breast cancer cells. Consistent with its selectivity, 3AC was
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found to lack any killing activity in the latter two, as neither breast cancer cell line
expresses SHIP1.
Of greater significance, the lead pan-SHIP inhibiting derivatives
themselves (K118, K141, K142, K149, K179) demonstrate even more potent cellkilling potential than their parent compounds (see figures 6-7). In nearly all
experiments against leukemia and breast cancer cells, aminosteroid derivative
K118 exhibits more notable cell killing than not only parent compound 3AC, but
all other aminosteroid derivatives as well (see figure 6). Even at concentrations as
low as 5µM, less than 35% of 697 cells survived; when looking at the NB4 cell
line, K118 killed approximately 85% cells at a slightly increased concentration of
12.5µM. Furthermore, it is important to note that this compound is water soluble,
making its potential even more exciting, especially from a pharmacological/
clinical perspective. The lead tryptamine derivative, K149, demonstrated more
potent cell killing ability than its parent (K103) and all other derivatives, against
every cell line, at nearly every concentration (see figure 7). Overall, 3AC
(aminosteroid) derivatives were more effective than 2PIQ (tryptamine) derivatives
(compare figures 6 and 7), and as may be expected, hematopoietic cancer cells
expressing both SHIP1 and SHIP2 showed a higher sensitivity to pan-SHIP
inhibitors than they did to 3AC which is selective only for SHIP1.

Inhibition of SHIP combats tumorigenesis in vivo
While the lead pan-SHIP inhibitors identified through this study are just
starting to be introduced to in vivo models, the effects of their parent compounds
(3AC, 2PIQ) have been well-characterized for comparison in this study. Dosages
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were adjusted based on each particular compound, but for the initial toxicity
screens, 3AC (also identified as K100) was administered and well-tolerated at 2526.5mg/kg, 2PIQ (also identified as K103) was administered and well-tolerated at
7.63mg/kg and 15.25mg/kg, but proved toxic at 22.88mg/kg (resulted in death).
Upon determining the maximum therapeutic dose in these otherwise healthy
C57Bl/6 mice, SCID mice, lacking the T cells and B cells of their adaptive
immune system, were challenged with multiple myeloma cells via intraperitoneal
injection then treated with the predetermined dosage of inhibitory compound (or
vehicle) six hours later (25mg/kg for 3AC, 12.5mg/kg for 2PIQ, and 0.3%
Klucel/H2O or 50% DMSO/PBS for vehicle). Mice were then injected daily for
one week (known as the induction phase) followed by biweekly injections of
3AC, 2PIQ, or vehicle for the remaining 15 weeks of the study (known as the
maintenance phase). In the mice treated with 2PIQ, we saw an increase in
neutrophils and myeloid derived suppressor cells, MDSCs, (consistent with our
findings from the initial toxicity study) (see figure 8), which helped to combat
tumorigenesis. However, 2PIQ was not well-tolerated by the hosts and many died
within the first several weeks of the study. Treatment with 3AC did not confer
such toxic effects and notably reduced the viability of multiple myeloma cells in
vivo. 100% of vehicle-treated mice (those not receiving any inhibitory compound)
developed significant tumor growth, while only 40% of 3AC-treated mice showed
any tumor growth whatsoever, many of which were minor (see figure 9). Most
importantly, we found that treatment with 3AC results in significantly enhanced
survival of mice post-multiple myeloma challenge (see figure 10). At the
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culmination of the tumor challenge study, more than twice the number of 3ACtreated mice survived than vehicle-treated mice. Again, it is important to
remember that 3AC is SHIP1 selective, and therefore, shall only confer results of
this nature to cancers of the blood and bone marrow. Hoping to expand the
clinical applicability of SHIP inhibition, we are currently beginning the same in
vivo trials with the lead pan-SHIP inhibitors identified thus far in the study, K118,
K141, K142, K149, K179. K118, K141, K142, and K179 are all derivatives of
3AC and hopefully will be tolerated as well, while K149 is a derivative of 2PIQ,
raising some concern regarding toxicity. These lead pan-SHIP inhibitors are
currently being tested at 5-15mg/kg in 5% DMSO:Saline, 5% DMSO:H2O, or in
100% H2O, depending upon their solubility.
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Discussion

The prevalent belief that PI3K signaling is counteracted by all lipid
phosphatases (Hamilton et al., 2011) is slowly being challenged (Kerr, 2011;
Fuhler et al., 2011). It has recently been shown that the hydrolysis of
PtdIns(3,4,5)P3 to PtdIns(3,4)P2 actually results in more efficient binding of Akt
(Franke et al., 1997), hence enhancing cell proliferation and survival effects.
Given the implication of the PI3K-Akt pathway in many different malignancies,
targeting its intricate components, such as SH2-domain containing inositol 5’
phosphatase, presents both an opportunity and a challenge for novel cancer
therapies. Because SHIP directly facilitates formation of the PtdIns(3,4)P2
product, researchers are now seeking ways to inhibit its intracellular enzymatic
activity. By decreasing PtdIns(3,4)P2 levels, it has been hypothesized that growth,
division, and survival signals will be decreased as well (Artemenko, 2009),
ultimately resulting in increased cell death. Targeting this phosphatase in cancer
treatment can be complicated by the existence its two paralogs; SHIP1 seems to
be expressed predominately in the hematopoietic compartment, while SHIP2
appears to be ubiquitously expressed. While previous work in the Kerr lab
identified the ability of a SHIP1 selective inhibitor to reduce viability of
malignant hematopoietic cells, little study has been done on the effects of SHIP2
inhibition, or more intriguingly, pan-SHIP inhibition. While we are not the first to
identify pan-SHIP inhibitors, to the best of our knowledge, we are the first to

17
propose pan-SHIP inhibition as a novel therapeutic approach in the treatment of
both hematopoietic and breast cancers.
In this study, we sought to expand upon work done previously in the lab
demonstrating the ability of 3 α-aminocholestane to reduce the viability of
multiple myeloma cells in vitro and in vivo. Via high throughput screening
methods, it was our goal to identify compounds capable of inhibiting both SHIP1
and SHIP2 simultaneously, hence affecting a broader range of malignancies. This
screen yielded five lead pan-SHIP inhibitors, which we refer to as K118, K141,
K142, K149, and K179. Throughout the course of this study, we have
demonstrated the ability of these pan-SHIP inhibitors to prevent the hydrolysis of
PtdIns(3,4,5)P3 to PtdIns(3,4)P2 in vitro, as well as to effectively reduce the
viability of leukemia, multiple myeloma, and breast cancers ex vivo. In vivo
studies are currently under way as described, but according to the preliminary
data we are obtaining, several of the lead pan-SHIP inhibitors appear to be both
well-tolerated by the host and effective at killing the multiple myeloma
malignancies with which the mice have been challenged.
In conclusion, findings of this study suggest that the inhibition of SHIP1
and SHIP2 provides a feasible technique for targeting and killing cancer cells of
various origins. While development of inhibitory compounds is still in
preliminary phases, the potency of lead pan-SHIP inhibitors to kill breast and
blood cancer cells has been clearly demonstrated. Our studies are currently being
pursued and extended and will hopefully lead to clinical trials using enhanced
derivatives of the most promising pan-SHIP inhibitors identified to date. Overall,
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our findings suggest that the inhibition of SHIP1 and SHIP2, collectively, may
provide a promising novel therapeutic approach in the treatment of both
hematopoietic and non-hematopoietic cancers. We are beyond excited to see
where these studies may lead us in the near future.

This work has been made possible by the generous financial support of the
NIH (RO1HL72523, RO1HL085590, RO1HL107127), Paige’s Butterfly Run, the
Carol M. Baldwin Breast Cancer Research Fund, and last but not least, the Renée
Crown University Honors Program at Syracuse University.
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FIGURE 1.1

Figure 1.. Enzymatic generation and hydrolysis of PI(3,4,5)P3 and PI(3,4)P2 at the
plasma membrane by lipid phosphatases. As one can see, PI3
PI3-kinases
kinases first
phosphorylate PI(4,5)P2 at the 3’ position of the inositol ring. This results in the
formation of PI(3,4,5)P3. Two classes of phosphatases can then act
ac on the PIP3
molecule in opposing ways. PTEN, a known tumor suppressor, dephosphorylates
PIP3 at the 3’ position, returning PI(3,4,5)P3 to PI(4,5)P2. SHIP, on the other
hand, dephosphorylates PIP3 at the 5’ position, resulting in the PI(3,4)P2 product.
(INPP4
NPP4 is negligible in the context of this study).

1

Taken from Kerr WG. (2011). Inhibitor and activator: dual functions for SHIP in immunity and
cancer. Annals of the New Yor
York Academy of Sciences. 1217: 1–17.
17. doi: 10.1111/j.174910.1111/j.1749
6632.2010.05869.x
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FIGURE 2.2

pET-24b(+)
24b(+) bacterial expression vector. In
Figure 2. Restriction map of pET
expression and purification process of human recombinant SHIP1,
SHIP1 the SHIP1
cDNA expression construct was amplifie
amplified
d by PCR from the pMIGR1 vector and
was subsequently inserted into the pET24b bacterial expression vector at the
EcoR1 and Xho11 restriction sites (see top right).

2

http://www.snapgene.com/resources/plasmid_files/pet_and_duet_vectors_
(novagen)/pET-24b(+)/
24b(+)/
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FIGURE 3.
A.3

Figure 3A. Malachite Green standard curve measuring free phosphate in solution.
The standard curve was generated using polynomial second order non-linear
non
regression analysis. In simplest terms, the greater the level of free inorganic
phosphate (in our study, liberat
liberated
ed by SHIP) the higher the absorbance.

B. Working stock calculation
___mg inhibitor x

1g
x
1mol
x 1L x
1000mg mol. weight(g) 0.010M

6

10 µl = ___ µl solvent
1L

Figure 3B. Calculation used to determine amount of solvent needed to make
10mM working stock of each inhibitory compound. This working stock was used
in the Malachite Green Assay at a final concentration of 1mM. For dilution
screens resulting in final concentrations of 500µM, 250µM,
M, and 125µM,
125
this
stock was subsequently added to equal volume of pure solvent (i.e. 200µl
200 of
10µM
M stock + 200
200µl DMSO = 5µM
M working stock, final concentration 500µM).
500

3

Taken from Echelon Biosciences, Inc. website at http://www.echelon
http://www.echelon-inc.com/content/EBI/
inc.com/content/EBI/
product/files/TDS_K--1501_rev1.pdf
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FIGURE 4.

Figure 4. Relative enzymatic activity of recombinant SHIP1/2 protein with
derivatives of parent compounds, as measured by Malachite Green (phosphate
(
release) assays.. Derivatives of aminosteroids ((top left), tryptamines (top
(
right) and
quinolines (bottom
bottom center
center) have been developed and tested in vitro by Malachite
Green assay and expressed as relative to solvent only control
control.. In each graph, the
parent compound is shown at leftmost position along x axis (i.e. 3AC, 2PIQ,
6PTQ). Only aminosteroid (3AC) and tryptamine (2P
(2PIQ)
IQ) derivatives showed
notable pan-SHIP
SHIP inhibition, and hence, were moved forward with in study. Of
particular interest at the culmination of all Malachite screens were compounds
K118, K141, K142, K149, and K179.
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FIGURE 5.

Fig. 5. Pan-SHIP inhibition reduces cell viability/induces
induces cell death of multiple
myeloma and breast cancer cells ex vivo. (A-C) Treatment of (A) OPM2 multiple
myeloma cells, (B) MDA-MB-231 breast cancer or (C) MCF-7
7 breast cancer cells
with 3AC, 1PIE, 2PIQ or 6PTQ decre
decreased cell survival in a dose--dependent
manner.. Consistent with it
its selectivity for SHIP1, 3AC lacked any killing activity
in the latter two breast cancer cell lines (B, C) which, as cancers outside of the
hematopoietic compartment, do not express SHIP1.
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FIGURE 6. Lead aminosteroid panSHIP1/2 inhibitors vs. parent
compound against leukemia and breast cancer cells

Lead aminosteroid derivatives vs. parent against pediatric leukemia cells

Lead aminosteroid derivatives vs. parent against adult leukemia cells

Lead aminosteroid derivatives vs. parent against breast cancer cells
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FIGURE 7.

Lead tryptamine, K149 vs. parent tryptamine K103 against pediatric leukemia cells

8.

Lead tryptamine, K149 , vs. parent ttryptamine,
ryptamine, K103, against adult leukemia cells

Lead tryptamine, K149, vs. parent tryptamine, K103, against breast cancer cells

FIGURE
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%
MDSC

Figure 8. Hemavet analysis of mice receiving 2PIQ treatment. According to
blood samples taken from mice treated with 2PIQ at two different concentrations,
we saw an increase in both neutrophils and myeloid derived suppressor cells
(MDSCs) when compared to mice receiving vehicle treatment.

FIGURE 9.
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A

B

Figure 9. Vehicle vs. 3AC-treated NSG Mice, Week 3, Xenogen IVIS-200
Optical In Vivo Imaging System. Based on luciferase bioluminescence, it is
apparent that 3AC significantly reduces the viability of OPM2 multiple myeloma
cells in vivo. (A) 100% of mice challenged with OPM2 cells and treated with
vehicle only (0.3% Klucel) exhibit significant tumor growth. (B) Only 40% of
mice challenged with OPM2 multiple myeloma cells then treated with 3AC have
developed any visible tumor growth. Of the two mice in this image demonstrating
tumorigenesis, one displays minimal tumor growth.

FIGURE 10.

28

Figure 10. Treatment with 3AC results in significantly enhanced survival of mice
post-multiple myeloma challenge. 3AC postponed the initial death event for the
group receiving treatment to 10 weeks, while the vehicle group began to
experience fatality at 7 weeks. More importantly, at the culmination of the 16week tumor challenge study, more than twice the number of 3AC-treated mice
survived than did vehicle-treated mice.

References

29

Alberts, B., Bray, D., Hopkin, K., Johnson, A., Lewis, J., Raff, M., Roberts, K., &
Walter, P. (2010). Essential cell biology. (3rd Ed. ed.). New York, New
York: Garland Science, Taylor & Francis Group.
Artemenko Y, Gagnon A, Sorisky A. (2009). Catalytically inactive SHIP2 inhibits
proliferation by attenuating PDGF signaling in 3T3-L1 preadipocytes. J
Cell Physiol. 218:228–36.
Baselga, J. (2011). Targeting the phosphoinositide-3 (PI3) kinase pathway in
breast cancer. The Oncologist. 16(Suppl 1):12–19.
Brooks R, Fuhler GM, Iyer S, Smith MJ, Park MY, Paraiso KH, Engelman RW,
Kerr WG. (2010). SHIP1 inhibition increases immunoregulatory capacity
and triggers apoptosis of hematopoietic cancer cells. J Immunol.
184:3582–9.
Bunney TD, Katan M. (2010). Phosphoinositide signalling in cancer: beyond
PI3K and PTEN. Nat Rev Cancer. 10:342–52.
Costantini, J. L., Cheung, S. M., Hou, S., Li, H., Kung, S. K., Johnston, J. B., ... &
Marshall, A. J. (2009). TAPP2 links phosphoinositide 3-kinase signaling
to B-cell adhesion through interaction with the cytoskeletal protein
utrophin: expression of a novel cell adhesion-promoting complex in B-cell
leukemia. Blood, 114(21), 4703-4712.
Franke TF, Kaplan DR, Cantley LC, Toker A. (1997). Direct regulation of the Akt
proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.
Science. 275:665–8.
Fuhler G. M., Brooks R., Toms B., Iyer S., Gengo E. A., Park M. Y., et al.
(2012). Therapeutic potential of SH2 domain-containing inositol-5′phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Mol. Med. 18 65–
75.
Hamilton MJ, Ho VW, Kuroda E, Ruschmann J, Antignano F, Lam V, Krystal G.
(2011). Role of SHIP in cancer. Exp Hematol. 39:2–13.
Harvey RD, Lonial S. (2007). PI3 kinase/AKT pathway as a therapeutic target in
multiple myeloma. Future Oncol. 3:639–47.
Hazen AL, Smith MJ, Desponts C, Winter O, Moser K, Kerr WG. (2009). SHIP is
required for a functional hematopoietic stem cell niche. Blood. 113:2924–
33.

30
Kerr WG. (2011). Inhibitor and activator: dual functions for SHIP in immunity
and cancer. Annals of the New York Academy of Sciences. 1217: 1–17. doi:
10.1111/j.1749-6632.2010.05869.x
Liu P, Cheng H, Roberts TM, Zhao JJ. (2009). Targeting the phosphoinositide 3kinase (PI3K) pathway in cancer. Nat Rev Drug Discov. 8(8): 627–644.
Ma K, Cheung SM, Marshall AJ, Duronio V. (2008). PI(3,4,5)P3 and PI(3,4)P2
levels correlate with PKB/akt phosphorylation at Thr308 and Ser473,
respectively; PI(3,4)P2 levels determine PKB activity. Cell Signal.
20:684–94.
Mandl A, Sarkes D, Carricaburu V, Jung V, Rameh L. (2007). Serum withdrawalinduced accumulation of phosphoinositide 3-kinase lipids in
differentiating 3T3-L6 myoblasts: distinct roles for Ship2 and PTEN. Mol
Cell Biol. 27:8098–112.
Rohrschneider LR, Fuller JF, Wolf I, Liu Y, Lucas DM. (2000). Structure,
function, and biology of SHIP proteins. Genes Dev.14:505–20.
Ruela-de-Sousa RR, Queiroz KC, Peppelenbosch MP, Fuhler GM. (2002).
Reversible phosphorylation in haematological malignancies: potential role
for protein tyrosine phosphatases in treatment. Biochim Biophys
Acta. 20101806:287–303.
Scheid MP, et al. (2002). Phosphatidylinositol (3,4,5)P3 is essential but not
sufficient for protein kinase B (PKB) activation; phosphatidylinositol
(3,4)P2 is required for PKB phosphorylation at Ser-473: studies using
cells from SH2-containing inositol-5-phosphatase knockout mice. J Biol
Chem. 277:9027–35.
Tu, Z., J. M. Ninos, Z. Ma, J. W. Wang, M. P. Lemos, C. Desponts, T. Ghansah,
J. M. Howson, W. G. Kerr. (2001). Embryonic and hematopoietic stem
cells express a novel SH2-containing inositol 5’-phosphatase isoform that
partners with the Grb2 adapter protein. Blood 98: 2028–2038
Wong K, Engelman JA, Cantley LC. (2010). Targeting the PI3K signaling
pathway in cancer. Curr Opin Genet Dev. 20 87-90.

31
Summary of Capstone Project

The phosphotidylinositol 3-kinase, or PI3K, pathway is one of the most
prominent cell proliferation and survival pathways in the human body. In a
healthy model, activation and deactivation of this pathway is carefully regulated
so as to allow for normal growth and the replacement of cells as needed. Upon
deregulation (typically due to mutations) however, this signal transduction system
can lead to the evasion of programmed cell death, the stimulation of a cell’s own
growth, and the ability of a cell to replicate indefinitely. Given that one of the
most fundamental definitions of cancer is an uncontrolled growth and
proliferation of abnormal cells, it is not surprising that many tumor cells are
observed to have hyperactivated PI3K signaling.
Through meticulous study, it has been found that the phosphorylation of a
regular cell membrane component, known as phosphatidylinositol(4,5)
bisphosphate to phosphatidylinositol(3,4,5)trisphosphate (“PIP3”) activates this
pathway, hence leading to increased cell growth and survival. For many years, it
has been assumed that if phosphorylation turns the pathway “on”, then
dephosphorylation ought to turn the pathway “off”. Dephosphorylation of PIP3
back to PIP2 is facilitated via two classes of lipid phosphatases: PTEN
(phosphatase and tensin homolog) and SHIP (SH2-domain containing inositol 5’
phosphatase). PTEN has been very well-characterized and functions as a known
tumor suppressor. By removing a phosphate group from the 3’ position of the
inositol ring of PIP3, PTEN returns PIP3 to PIP2 in the “4,5” form (i.e.
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phosphatidylinositol (3,4,5) trisphosphatephosphatidylinositol (4,5)
bisphosphate). In doing so, PTEN prevents downstream components of the
pathway (primarily the protein kinase, “Akt”) from binding to PIP3 and
subsequently, signaling is discontinued. More recently discovered, the other class
of phosphatase, SHIP, removes a phosphate group from the 5’ position of the
inositol ring, hence returning PIP3 to PIP2 in the “3,4” form (i.e.
phosphatidylinositol (3,4,5) trisphosphatephosphatidylinositol (3,4)
bisphosphate). Unlike the “4,5” product, this “3,4” product actually seems to bind
the downstream component Akt even more efficiently that does PIP3, and hence,
enhances signaling leading to cell growth, proliferation, and survival.
Because SHIP directly facilitates hyperactivation of the PI3K pathway, cancer
biologists in the Kerr laboratory at SUNY Upstate Medical University are now
looking for ways to inhibit its functioning. At this time, the molecular structure of
SHIP has not been determined; therefore designing specific compounds to bind to
and block the protein’s action is not a feasible option. Further challenging to the
development of a specific and effective inhibitor is the fact that SHIP has two
paralogs, or two copies of the gene that vary slightly. SHIP1 expression seems to
be restricted to cells of the hematopoietic compartment (meaning those that form
your blood and bone marrow cells), whereas SHIP2 seems to be ubiquitously
expressed in cells throughout the body. Based on the properties of the SHIP
molecule that are known, previous work in the Kerr lab identified a SHIP1selective inhibitor known as 3 α-aminocholestane (3AC), that proved capable of
killing hematopoietic malignancies in mice. This inhibitor was far from perfect,
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however. As mentioned, 3AC is SHIP1-selective, meaning that it does not target
the other form of the protein, SHIP2, which in the compound’s presence is still
able to hydrolyze PIP3PIP2. Given that SHIP1 expression is limited only to the
hematopoietic domain, 3AC provides a feasible approach only in the treatment of
blood cancers, and remains ineffective in the treatment of other nonhematopoietic cancers (i.e. tissue cancers). Likewise, this compound is relatively
insoluble; in order to work with 3AC in any in vitro or in vivo trials, it first must
be dissolved in 100% ethanol at 100 °C, clearly not advantageous from a
pharmacological perspective. Furthermore, during in vivo studies, 3AC was
observed to confer slight toxicity to its hosts.
Therefore, the goal of this study over the past two years has been to
identify a new, more effective inhibitor that circumvents the challenges associated
with 3AC. In close collaboration with Dr. John Chisholm’s organic chemistry lab
at Syracuse University, who have synthesized more than 100 potential inhibitors,
I have pursued a high throughput screening strategy to identify compounds with a
higher solubility and lesser toxicity, capable of inhibiting the intracellular
enzymatic activity of both SHIP1 and SHIP2. Through an in vitro technique
known as the Malachite Green Assay, I was able to identify compounds that
prevented SHIP1/2 from removing the phosphate group at the 5’ position of the
PIP3 inositol ring. Upon completion of the Malachite screen on all compounds,
those demonstrating the most significant inhibition were then carried into ex vivo
trials. During this phase, compounds were introduced directly on to cell lines at
varying concentrations to test their ability to reduce cell viability. Cell lines
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studied included adult and pediatric leukemia, multiple myeloma, and breast
cancer, allowing us to observe the effects of pan-SHIP inhibition on both
hematopoietic and non-hematopoietic cancers. All of our lead pan-SHIP inhibitors
demonstrated notable cell-killing activity against blood and breast malignancies.
Lastly, the lead inhibitors identified through in vitro and ex vivo studies were then
entered into in vivo trials. Compounds were initially administered at
predetermined dosages to otherwise healthy mice in order to observe inherent
toxic effects, if any. Upon completion of the toxicity screens, SCID (severe
combined immunodeficient) mice were challenged with multiple myeloma cells,
then subsequently treated with our panSHIP inhibitors. These mice are deficient
in the T cells and B cells of the adaptive immune system, and therefore, if tumor
growth is prevented or reduced, we know it is a direct result of the treatment they
are receiving. This phase of the study is currently underway, but according to the
preliminary data we are obtaining, several of the lead pan-SHIP inhibitors appear
to be both well-tolerated by the host and effective at killing the malignancies with
which the mice have been challenged.
Findings of this study suggest that the inhibition of SHIP1 and SHIP2
provides a feasible technique for targeting and killing cancer cells of various
origins. While development of inhibitory compounds is still in preliminary
phases, the potency of lead pan-SHIP inhibitors to kill breast and blood cancer
cells has been clearly demonstrated. Our studies are currently being pursued and
extended and will hopefully lead to clinical trials using enhanced derivatives of
the lead pan-SHIP inhibitors identified to date. Overall, our findings suggest that
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the inhibition of SHIP1 and SHIP2 may provide a promising novel therapeutic
approach in the treatment of both hematopoietic and non-hematopoietic cancers,
revolutionizing chemotherapy as it is currently known.

